Introduction {#S1}
============

Polymyalgia rheumatica (PMR) is a common condition characterized by inflammatory pain and stiffness in the shoulder and in the pelvic girdle and neck. It occurs in people over the age of 50, and is associated with an acute-phase response, a rapid response to low doses of glucocorticoids (GC), and a favorable prognosis. Giant cell arteritis (GCA) is a large vessel vasculitis associated with PMR in about half of cases, suggesting that the two disease could be different or progressive aspects of the same disease.

Previous studies reported an increased risk of infections before PMR and GCA \[[@ref1]--[@ref3]\] and other studies analyzed specific infective triggers (e.g. herpes virus) for GCA/PMR \[[@ref1], [@ref4]\].

Moreover, there are case reports of subjects who developed PMR following influenza vaccination \[[@ref3], [@ref5], [@ref6]\]. Vaccine components, such as adjuvants, can activate the immune system and induce inflammatory manifestations (also defined as autoimmune/inflammatory syndrome induced by adjuvants).

In both cases, different biological mechanisms have been proposed to explain the link between infective agents or vaccinations and development of GCA/PMR. Preexisting immune system alteration due to genetic polymorphisms could increase the deregulated inflammatory response. Moreover, immune senescence has been described as adaptive and innate immune deregulation in the elderly, with excessive and prolonged production of pro-inflammatory cytokines \[[@ref7], [@ref8]\]. In the elderly, also a relative deficit of activation in the hypothalamic--pituitary--adrenal (HPA) axis could be responsible for a deregulated response to environmental stresses \[[@ref9]--[@ref11]\].

The aim of this study was to investigate the frequency of environmental triggers before the onset of PMR and the association between presence of triggers and clinical characteristics using a retrospective cohort study within a secondary care database.

Material and methods {#S2}
====================

In order to define the association of PMR with infections or vaccines as environmental triggers of the disease, we retrospectively analyzed the database of 58 PMR patients consecutively recruited from a single rheumatology secondary care setting between January 2003 and December 2017. All the PMR patients satisfied the Bird criteria (until 2012) \[[@ref12]\] and 2012 ACR/EULAR criteria (beyond 2013) \[[@ref13]\] and were followed for at least 24 months, with essentially the same diagnostic and management modalities reported in a previous work \[[@ref3]\].

The patients were all referred to a rheumatologist by general practitioners, who agreed to refer suspected PMR cases prior to GC therapy, with basal laboratory tests: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), serum electrophoresis, rheumatoid factor (RF), anticyclic citrullinated peptide antibodies (ACPA Abs), antinuclear antibodies (ANA), creatine kinase (CK), complete blood count, renal and liver function, serum urate, and urinalysis. Exclusion criteria were prior steroid therapy or preexisting mimicking diseases. X-rays of the hand and foot were obtained, to exclude signs of erosive arthritis and/or chondrocalcinosis. Some further investigations (e.g. thorax radiography, abdomen US) were carried out when necessary.

At the first visit, patients underwent routine multidistrict ultrasound (US) examination of both proximal (shoulder, hip) and distal sites regardless of the presence of signs or symptoms of inflammatory involvement, with a Sono Site (Bothell, USA) Titan with a multifrequency linear 5--10 MHz probe (until 2015) and an Esaote (Genova, Italy) MyLab Gamma with multifrequency linear 6--13 MHz probe (after 2015). Each synovitis was scored as 0 (absent), 1 (mild), or 2 (significant) and for statistical purposes the higher score for each site was recorded.

The glucocorticoid therapy scheme followed previous recommendations, with a initial daily dose of 16 mg methylprednisolone (20 mg prednisone equivalent daily), whereas in patients with relevant comorbidities (in particular diabetes, glaucoma), a lower dose was preferred \[[@ref14]\]. The initial dose was maintained for 10--15 days, then tapered to 12 mg for 15--20 days, to reach a daily dose of 8 mg within 4--8 weeks, and then 4 mg for another 4--8 weeks. Once remission was achieved the dose was tapered under 4 mg by 1 mg every 4 weeks until discontinuation given that remission was maintained.

Laboratory tests were generally repeated after a month from the first visit (when corticosteroid therapy was started) and about every three months in the follow-up. For each patient information on gender, age, systemic symptoms, and possible environmental triggers, was collected. In particular, the possible environmental trigger was recorded if it occurred within three months from onset of polymyalgic symptoms and if the patient him- or herself judged this event as correlated to his or her symptoms. For each case we also defined the time (in months) to normalization of inflammatory reactants. We defined dependency on GC when a dose of GC (equal or less than 4 mg methylprednisolone, or 5 mg prednisone equivalent daily) remained necessary to avoid myalgic symptoms, despite a persistent remission of inflammatory reactants and absence of synovitis on US.

Statistical analysis was performed using the GraphPad InStat 3 package (GraphPad Software Inc, La Jolla, CA, USA). Multivariate and univariate linear regression analysis was applied to test the effects of variables on outcome and to define its correlation. The non-parametric Spearman rank test was applied to correlate variables. The two-tailed unpaired *t*-test was used to compare means between the two groups, whereas Fisher's exact test was used to compare the percentages between the two groups for categorical variables. The level of statistical significance was set at a *p*-level of 0.05.

Results {#S3}
=======

Median age at the time of diagnosis was 71 years (range 63--89) and 60% were female (35 females, 23 males). Median ESR and CRP were 51 mm/h (range 6--99, normal value \< 21) and 3 mg/dl (range 0.5--1.3, normal value \< 0.5) respectively. The mean time to normalize the inflammatory reactant was 6.9 months (range 4--12) ([Table I](#T1){ref-type="table"}).

###### 

Demographic, laboratory, and ultrasonographic characteristics of patients with polymyalgia rheumatica, and subgroups with or without environmental trigger before disease onset

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                          Total                  PMR with trigger         PMR without trigger     *p* (test)
  ---------------------------------------- ---------------------- ------------------------ ----------------------- ----------------------------------
  PMR patients (females/males)             58 (35/23)             15 (9/6)                 43 (26/17)              0.99 -- ns\
                                                                                                                   (two-sided Fisher's exact test )

  Age, years (range)\                      71 (63--89)\           74.6 (66--86)\           70.8 (63--89)\          0.0697 -- ns\
  SD                                       7.16                   6.98                     SD 6.81                 (unpaired *t*-test)

  Mean ESR at onset (range)\               51 mm/h (6--99)\       59 mm/h\                 49 mm/h\                0.1119 -- ns\
  SD                                       21.18                  (24--83) SD 19.51        (6--99) SD 21.01        (unpaired *t*-test)

  Mean CRP at onset (range)\               3 mg/dl (0.5--11.3)\   6.8 mg/dl (2.3--11.3)\   2.4 mg/dl (0.5--7.8)\   0.0113\*\
  SD                                       5.94                   2.62                     6.29                    (unpaired *t*-test)

  Disease duration, months\                6.9\                   4.8\                     7.6\                    0.0005\*\*\
  SD                                       2.72                   1.27                     2.82                    (unpaired *t*-test)

  GC dependence\                           25/58                  10/15                    15/43                   0.0398\*\
  (see text for definition)                                                                                        (two-sided Fisher's exact test)

  US mean score shoulder: GH (range)\      0.7 (0--2)\            0.1 (0--1)\              0.9 (0--2)\             0.0018\*\*\
  SD                                       0.86                   SD 0.4                   0.92                    (unpaired *t*-test)

  US mean score shoulder: SA-SD (range)\   1.3 (0--2)\            1.1 (0--2)\              1.4 (0--2)\             0.2410 -- ns\
  SD                                       0.87                   SD 0.91                  0.84                    (unpaired *t*-test)

  US mean score shoulder: LHBT (range)\    1.2 (0--2)\            0.8 (0--2)\              1.3 (0--2)\             0.0561 -- ns\
  SD                                       0.83                   SD 0.71                  0.91                    (unpaired *t*-test)

  US mean score hip (range)\               0.4 (0--2)\            0.2 (0--2)\              0.6 (0--2)\             0.1805 -- ns\
  SD                                       0.82                   SD 0.70                  0.93                    (unpaired *t*-test)
  ---------------------------------------------------------------------------------------------------------------------------------------------------

CRP -- C-reactive protein, ESR -- erythrocytesedimentationrate, GC -- glucocorticoids, GH -- gleno-humeral joint, LHBT -- longhead of biceps tendon, PMR -- polymyalgiarheumatica, SA-SD -- subacromial-subdeltoid bursa, SD -- standard deviation, US -- ultrasound, \* p \< 0.05, \*\* p \< 0.01, ns -- not significant.

Fifteen patients (26%) with PMR described a connection with environmental agents: six PMR patients reported a vaccination before the onset of disease(4 with influenza vaccine, 2 with tetanus toxoid vaccine); 3 reported an upper respiratory tract infection and 1 lower respiratory tract infection (pneumonia) before the onset of disease. Five patients reported seasonal influenza as a trigger of its PMR. In three patient a concurrent GCA was suspected, but none of these reported an environmental trigger.

The model of multivariate linear regression which better predicted a shorter time to normalize inflammatory reactant (*R^2^*27.46%, *p* = 0.0042) comprised the presence of an environmental trigger and a higher CRP. A linear regression analysis confirmed an inverse correlation between CRP at onset and time to normalize the inflammatory reactant (*r* = --0.3031, *p* = 0.0208). Spearman rank test between variables demonstrated a significant correlation between presence of an environmental trigger and shorter time to normalize inflammation (*r* = --0.5215, *p*\< 0.0001), and lower frequency of gleno-humeral synovitis on US (*r* = --0.3774, *p* = 0.0038). The results were confirmed by comparison of means between the two groups ([Table I](#T1){ref-type="table"}).

The presence of an environmental trigger failed to demonstrate correlations with ESR at diagnosis, fever, systemic symptoms, hip synovitis, subacromial-subdeltoid bursitis, long head of biceps tendon tenosynovitis or distal synovitis on US examination, gender and age ([Table I](#T1){ref-type="table"}).

In 10 patients who reported an environmental trigger before the onset of PMR, a very low dose of GC remained necessary to avoid myalgic symptoms, despite a persistent remission of inflammatory reactants and absence of synovitis on US; this aspect appeared significantly more frequent in the group with an environmental trigger (*p* = 0.0398, [Table I](#T1){ref-type="table"}). No cases of GCA were suspected in these patients during the follow-up.

Discussion {#S4}
==========

Even if a few studies did not demonstrate a seasonal pattern or association with infections in PMR and GCA \[[@ref15], [@ref16]\], the association between PMR and influenza vaccination and/or infections is well known and reported in several case reports and case series \[[@ref1]--[@ref6]\]. Our data support these findings and provide the largest case series of PMR triggered by infection or vaccinations among an elderly population in south-eastern Tuscany. Considering the notably high number of years encompassed by our retrospective analysis, a direct correlation with any specific subtype of vaccine, which varies year per year, can be excluded.

In this study an environmental trigger was reported in almost a quarter of cases. These data suggest that PMR triggered by an environmental factor could constitute a different subset of milder disease, as they have a more rapid response to GC therapy with a higher CRP at diagnosis. Moreover, in these patients US could reveal lesser gleno-humeral synovitis. An inverse correlation between higher CRP at onset of PMR and impaired activation of HPA axis has been demonstrated \[[@ref10]\]. Interestingly, a subset of PMR with similar clinical (higher CRP, faster response to glucocorticoids) and imaging characteristics (mainly extracapsular hip involvement detected with whole-body magnetic resonance) was recently described \[[@ref17]\]. Moreover, those patients with an extracapsular pattern were less likely to be able to stop GC therapy within the first year \[[@ref17]\].

Also in our case study 66% of patients with an environmental trigger showed significant difficulties to stop GC therapy. This aspect could suggest that in this subgroup of patients a previous HPA axis impairment could give a higher susceptibility to abnormal responses to stresses (polymyalgic phase) but also to a subsequent necessity of substitutive hormonal replacement (dependence on low GC doses) once remission is obtained.

Further studies could be useful to determine whether this subset of PMR patient should be reclassified as having definite immunological deregulation and HPA axis impairment, where low doses of GC constitute a substitutive hormonal therapy \[[@ref9], [@ref10]\]. A prodromal phase to musculoskeletal symptoms, with fatigue and sleep problems, has been previously described, and it could be consistent with this immune-endocrinologic deregulation \[[@ref18]\].

Even if our retrospective data cannot provide information about the endocrinologic, immunological and genetic state of our PMR patients, our data support the hypothesis that an infective and immunological stimulus in an elderly patient can exert excessive and prolonged production of pro-inflammatory cytokines as described in the condition defined as immunosenescence, an adaptive and innate immune deregulation in the elderly \[[@ref7], [@ref8]\]. These hypotheses are consistent with the findings of the recently published Danish population-based study, whose authors found a higher risk of infections before the development of PMR \[[@ref1]\].

Conclusions {#S5}
===========

Our paper is the first one evidencing a strict correlation between CRP at diagnosis, response to therapy and environmental trigger. We may suppose that our patients belong to a more specific subtype of PMR, in whom external stimuli, such as vaccination or infection, may lead to an inappropriate response within the context of impaired immune and endocrine systems.

We recommend systematic research of previous infection or vaccination in patients with recent onset of PMR.

Despite important advances in the treatment of PMR and GCA, etiology remains an intriguing matter of debate. We hope that our findings will represent a new step forward in its comprehension, but further studies are needed.
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